Benevolence

Driving Impact with AI: Brian Impact Foundation Joins AVPN Global Conference 2024

Retrieved on: 
Friday, April 26, 2024
Benevolence, Social change, Impact, AI, Conference, Artificial intelligence, Artificiality, Data collection, Organization, Medical device

Brian Impact attends Asian Venture Philanthropy Network Global Conference 2024 to discuss foundation's AI-powered assistance system, 'BEES (Benevolence Enhancing Expert System)'

Key Points: 
  • Brian Impact attends Asian Venture Philanthropy Network Global Conference 2024 to discuss foundation's AI-powered assistance system, 'BEES (Benevolence Enhancing Expert System)'
    Panel discussion on "Leveraging Artificial Intelligence for Philanthropic Impact" alongside global representatives from Wadhwani AI, Impact Intelligence, Tony Blair Institute for Global Change, and Micron Foundation
    SEOUL, South Korea, April 26, 2024 /PRNewswire/ -- Brian Impact Foundation recently attended Asian Venture Philanthropy Network (AVPN) Global Conference 2024 held in Abu Dhabi, the United Arab Emirates, and deliberated on the potential of Artificial Intelligence tackling societal challenges in transformative ways.
  • The session featured a distinguished panel comprising global representatives from Wadhwani AI, Impact Intelligence, Tony Blair Institute for Global Change, and Micron Foundation.
  • AVPN, Asia's leading network for impact organizations, investors, and stakeholders with a social innovation mandate, has been hosting the annual AVPN Global Conference since 2013.
  • This year's AVPN Global Conference 2024 took place April 23-25 in Abu Dhabi, themed "One Asia, One Future."

BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers

Retrieved on: 
Monday, March 25, 2024
Professional Services, Health, Finance, Clinical Trials, Research, Science, Pharmaceutical, PDE10, Phases of clinical research, Ulcerative colitis, Brain, IL6, Disease, Tumor necrosis factor, Central nervous system, IL8, Benevolence, Patient, CNS, CGMP, UC, Camp, Șaeș, Trial of the century, BAI, Cytokine, Drug development, Safety, Inflammatory bowel disease, Euronext Amsterdam, Steroid, JAK, Pharmaceutical industry

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.
  • As a result, BenevolentAI’s scientists designed BEN-8744 to be not only a potent PDE10 inhibitor, but also a peripherally-restricted molecule, i.e.
  • The Phase Ia study results support this profile, showing no evidence of CNS-associated adverse events at any dose level.
  • It is anticipated that the full results from this study will be presented in a peer-reviewed forum at a later date.

BenevolentAI Appoints New Chief Technology Officer

Retrieved on: 
Wednesday, March 20, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Health Technology, Professional Services, Machine learning, EBI, Elsevier, Bioinformatics, Drug discovery, University of Edinburgh, Artificial intelligence, Benevolence, AI, Doctor of Philosophy, Engineering, BAI, Family, Euronext Amsterdam, European

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.
  • The Company is pleased to announce the appointment of Dr. James Malone as BenevolentAI’s new Chief Technology Officer.
  • As Chief Technology Officer at SciBite, James helped build software using ontologies, machine learning and knowledge graphs to analyse scientific data.
  • Specifically, his experience in building technology to support R&D within biotech will help with the continuing development of the BenevolentAI PlatformTM, which is critical for us to deliver cutting edge AI-driven drug discovery.”
    Dr. James Malone, incoming Chief Technology Officer, commented: “I’m excited to join the leadership team at BenevolentAI.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer

Retrieved on: 
Wednesday, January 24, 2024
Health, Technology, Other Science, Research, Artificial Intelligence, Science, Pharmaceutical, Development, Patient, BAI, Euronext Amsterdam, Executive Committee, MD, Culture, Artificial intelligence, Benevolence, AI, Ruhr University Bochum, Drug discovery, Doctor of Philosophy, LEO, Leo Pharma, EVP, Platform, Growth, Medical device

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect.

Key Points: 
  • BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect.
  • Dr. Joerg Moeller, MD, PhD, brings a wealth of experience to BenevolentAI.
  • Dr. François Nader, Chair of BenevolentAI, commented: “Along with the rest of the Board, I am delighted to welcome Joerg.
  • With his track record of delivering growth through driving performance, I am confident that Joerg will leverage our proprietary and validated Benevolent Platform™ to deliver our patient-centric revenue generating strategy.”
    Dr. Joerg Moeller, Chief Executive Officer of BenevolentAI, commented: “I am excited by the opportunity to lead BenevolentAI.

BenevolentAI: Shareholder Letter December 2023

Retrieved on: 
Thursday, December 28, 2023
Technology, Research, Finance, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Knowledge, Biology, Drug, Conference, Culture, Merck Group, Drug discovery, Medicine, ALS, AstraZeneca, Business, Data, UC, Retinoic acid receptor alpha, PDE10, AI, Business development, ID, Glioblastoma, Food, SAD, Merck, GBM, Growth, Benchmarking, Patient, Safety, Benevolence, Acceleration, Heart failure, Neurology, Ulcerative colitis, Pharmaceutical industry

Despite 2023 being a challenging year and a transition period for BenevolentAI, we have made significant progress in executing our strategic plan.

Key Points: 
  • Despite 2023 being a challenging year and a transition period for BenevolentAI, we have made significant progress in executing our strategic plan.
  • We were pleased with the signing of the new strategic collaboration with Merck KGaA in September.
  • We also introduced a new state-of-the-art target prediction methodology, which continues to enhance our previous target prediction fleet and target explanations.
  • As announced in our interim results announcement in September, we expect that headcount will be around 260 employees at the end of 2023.

Artificial Intelligence (AI) in Genomics Market to Surpass US$ 19.72 Billion by 2030 - Coherent Market Insights

Retrieved on: 
Wednesday, November 22, 2023
Translation, Research, Therapy, University, Benevolence, Patient, Medicine, Machine learning, Hitachi, Analysis, Drug discovery, End user, Partnership, IBM, Growth, AI, MICROSOFT, Pharma, Education, GENETICS, Medical device, Fine chemical, Function, Genomics, NVIDIA

The global artificial intelligence (AI) in genomics market is experiencing strong growth owing to the increasing biomedical and genomic datasets, growing adoption of AI-based solutions, rising focus on reducing turnaround time in drug discovery & diagnostics.

Key Points: 
  • The global artificial intelligence (AI) in genomics market is experiencing strong growth owing to the increasing biomedical and genomic datasets, growing adoption of AI-based solutions, rising focus on reducing turnaround time in drug discovery & diagnostics.
  • Growing awareness among healthcare professionals and the public about the benefits of AI in genomics is augmenting acceptance and demand for AI technologies in the genomics market.
  • Key players in the global artificial intelligence (AI) in genomics market include Fabric Genomics, International Business Machines, MICROSOFT, NVIDIA, AI Therapeutics, Ares Genetics, Benevolent AI, Deep Genomics, DIPLOID and among others.
  • Global Artificial Intelligence (AI) in Genomics Market Segmentation:

Artificial Intelligence (AI) in Genomics Market to Surpass US$ 19.72 Billion by 2030 - Coherent Market Insights

Retrieved on: 
Wednesday, November 22, 2023
Translation, Research, Therapy, University, Benevolence, Patient, Medicine, Machine learning, Hitachi, Analysis, Drug discovery, End user, Partnership, IBM, Growth, AI, MICROSOFT, Pharma, Education, GENETICS, Medical device, Fine chemical, Function, Genomics, NVIDIA

The global artificial intelligence (AI) in genomics market is experiencing strong growth owing to the increasing biomedical and genomic datasets, growing adoption of AI-based solutions, rising focus on reducing turnaround time in drug discovery & diagnostics.

Key Points: 
  • The global artificial intelligence (AI) in genomics market is experiencing strong growth owing to the increasing biomedical and genomic datasets, growing adoption of AI-based solutions, rising focus on reducing turnaround time in drug discovery & diagnostics.
  • Growing awareness among healthcare professionals and the public about the benefits of AI in genomics is augmenting acceptance and demand for AI technologies in the genomics market.
  • Key players in the global artificial intelligence (AI) in genomics market include Fabric Genomics, International Business Machines, MICROSOFT, NVIDIA, AI Therapeutics, Ares Genetics, Benevolent AI, Deep Genomics, DIPLOID and among others.
  • Global Artificial Intelligence (AI) in Genomics Market Segmentation:

BenevolentAI: Interim Results for the Six Months Ended 30 June 2023

Retrieved on: 
Thursday, September 21, 2023
Technology, Research, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Knowledge, Acceleration, Serum response factor, Katherine, Interim, Chronic kidney disease, Normalization, ALS, GBM, Retinoic acid receptor alpha, Sustainability Accounting Standards Board, PDE10, Sutro Biopharma, Dragon (magazine), Glioblastoma, Benevolence, AstraZeneca, Ulcerative colitis, BAI, Nouvelle AI, Euronext, UC, SLS, Euronext Amsterdam, Drug discovery, Heart failure, Merck, AI, IPF, CKD, Neurology, Idiopathic pulmonary fibrosis, Success, Conference, Pharmaceutical industry, Management, Sales, Medical device, Cryptocurrency, IND

BenevolentAI (Euronext Amsterdam: BAI) (“BenevolentAI” or the “Company” or the “Group”), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2023.

Key Points: 
  • BenevolentAI (Euronext Amsterdam: BAI) (“BenevolentAI” or the “Company” or the “Group”), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2023.
  • We committed in May to right-sizing the business which has resulted in an extension of our cash runway to at least mid-2025.
  • In particular, I want to thank Joanna for her commitment over the last five years to build the business into what it is today.
  • Operating cash flow before changes in working capital reduced by 22% from £48.4 million (H1 2022) to £37.9 million.

New Preclinical Data on AI-Generated Target Identified in BenevolentAI and AstraZeneca Collaboration Presented at ATS 2023

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Technology, Health, Pharmaceutical, Communications, Other Science, Research, Software, Artificial Intelligence, Media, Science, Artificial intelligence, Serum response factor, Small RNA, BAI, CRISPR, AI, Euronext, IPF, SRF, Conference, Benevolence, Idiopathic pulmonary fibrosis, AstraZeneca, Medical device

BenevolentAI ​​(Euronext Amsterdam: BAI), a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, announces that AstraZeneca presented new preclinical data on an AI-generated target identified in their ongoing collaboration with BenevolentAI.

Key Points: 
  • BenevolentAI ​​(Euronext Amsterdam: BAI), a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, announces that AstraZeneca presented new preclinical data on an AI-generated target identified in their ongoing collaboration with BenevolentAI.
  • The data was presented at the ATS International Conference 2023.
  • The research provides further scientific information on Serum Response Factor (SRF) as a potential target for idiopathic pulmonary fibrosis (IPF).
  • These data indicate that inhibition of SRF-driven transcription of pro-fibrotic genes in lung fibroblasts might deliver antifibrotic efficacy in IPF.